Principal, National Sector Leader for HCLS, KPMG US
Healthcare Life Sciences
KPMG is a leader in The Forrester New WaveTM in Healthcare RPA
Provides insights on how the political and regulatory environment, and market factors may impact investment decisions.
HHS final rule requires pharmacy benefit managers to pass along prescription drug rebates to patients at the point of sale
On November 20, 2020, the Centers for Medicare and Medicaid Services announced the Most Favored Nation Drug Pricing Model
By 2030, generics manufacturers will need to shift from the status quo and explore one of three avenues for change.
HHS, Department of Labor, and Treasury finalized price transparency requirements for health plans set to take effect beginning in 2022
FDA finalized a rule and guidance allowing states to submit prescription drug importation proposals and manufacturers to re-label drugs for importation
An Executive Order directs HHS rulemaking for “most favored nations” pricing for Medicare Part B and D drugs
As telemedicine accelerates, the need for greater tax clarity and updated guidance relating to virtual healthcare is evident.
Four Executive Orders (EO) described as action to deliver lower prescription drug prices to American Patients.
Failing to resume clinical trials could present as many risks to certain patients as COVID-19
An opportunity for medical device companies to shape their future customer base
The Life Sciences Industry is moving towards a dramatically different future based on a number of market drivers.
Private labs seeking to restructure or build to deploy COVID-19 testing operations can benefit from KPMG’s rapid start-up approach
For businesses making decisions about when and how to reopen their businesses, here is a practical guide to key considerations.
Implications for Healthcare providers
CMS just announced alternative Part D options that lower seniors’ cost-sharing for insulin, according to the attached issue brief.
To learn more about enhancements to CMS’s Accelerated & Advance Payment Program to help providers & suppliers during COVID.
Economic support and stimulus bill
Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.
Despite progress, companies are still facing many questions
Forward-thinking Life Sciences CXOs will transform Quality from a cost center to a value creator
Key insights and opportunities to unlock additional value by streamlining Regulatory Affairs operational activities
Despite progress in corporate cybersecurity, life sciences operational technology is still vulnerable to increasingly sophisticated threats.
Building a culture of excellence in healthcare
Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.
Proposed safe harbor changes open for comment
Consider applying for the voluntary initiative
Rising to the data challenge
2019 Health Care & Life Sciences Investment Outlook
Reinvent innovation and become an R&D front-runner by 2030
Unlocking value for life sciences organizations
This CIO Survey is the largest IT leadership study in the world, and summarizes what we learned about the transformational CIO.
KPMG/RAPS survey illustrates the ground medical device companies still have to cover
2018 Program benchmark report
Identifying opportunities for life sciences manufacturers.
Innovation in the life sciences finance function
As new entrants and cross-sector models abound, which direction should healthcare organizations turn?
Blockchain could be a key to interoperability and privacy
New standard. New challenges.
Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.
Register to receive timely insights
Meet our team